MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS) today announced the appointment of Michael S. Wygza to its board of directors. Wygza most recently served as President, Chief Executive Officer and a member of the board of directors of Radius Health, Inc.
“Michael’s impressive corporate leadership track record, deep life sciences industry expertise and extensive finance background make him a valuable addition to our board,” said Kevin Conroy, CEO and chairman of Exact Sciences. “Michael understands the complexities of bringing new tests to patients. He will be a critical asset to Exact Sciences as we advance our pipeline of new cancer screening technologies and expand patient and provider access to Cologuard®, the first FDA-approved noninvasive stool DNA screening test for colorectal cancer.”
At Exact Sciences, Wygza will serve as a member of the Board’s Audit Committee where he brings more than two decades of experience leading corporate finance divisions with some of the nation’s foremost biopharmaceutical companies. From 2011 to 2013, he served as President, CEO and board member of Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions. Prior to Radius, he held multiple senior management roles at Genzyme Corporation, including Chief Financial Officer from 1999 to 2011 and Executive Vice President of Finance from 2003 to 2011. He currently serves as a director for pharmaceutical companies Akebia Therapeutics, Inc. and Oncomed Pharmaceuticals, Inc. Wygza received his B.S. from Suffolk University and his M.B.A. from Providence College.
For more information on Cologuard, visit www.CologuardTest.com.
About Exact Sciences Corp.
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is included in the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at www.exactsciences.com, follow us on Twitter @ExactSciences or find us on Facebook
Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.